Related Experiment Video
Updated: Jun 5, 2026
Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers
Published on: July 21, 2017
Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain
1Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140, USA.
Abstract:
Use of siRNA for silencing major oncogenic/chemoresistance targets such as survivin has strong potential for cancer therapy. However, a key clinical limitation is their short action, preventing them from sustaining their therapeutic RNA-interference activity for optimal chemosensitization. This issue is tackled from the perspective of intracellular siRNA kinetics using a novel lipid-based "nanostructured siRNA carrier" (NSC), which incorporates variable amount of oil phase into the solid-lipid matrix to modify its siRNA release behaviors. We demonstrate that by manipulating the degradation responses of NSC device to lysosomal enzyme, tailoring of intracellular siRNA kinetics is achievable. A tailored NSC design delivering survivin-siRNA can extend the survivin knockdown period to 9 days, translating into steady, effective in vitro and in vivo chemosensitization of prostate cancer to docetaxel for over a week. All in all, this new NSC design provides a convenient mean to set up a clinically more appealing weekly or longer dosing cycle for siRNA therapy, which addresses a significant unmet need for prostate cancer treatment and is potentially useful for other chronic disease conditions as well.
Insights
This study introduces a novel nanostructured siRNA carrier (NSC) to overcome the short action of siRNA in cancer therapy. The NSC extends survivin knockdown for over a week, improving prostate cancer chemosensitization.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Therapy
Background:
- Small interfering RNA (siRNA) shows promise for cancer treatment by silencing oncogenes like survivin.
- A major clinical hurdle for siRNA therapy is its short duration of action, limiting sustained therapeutic effects.
- Effective chemosensitization requires prolonged RNA interference activity, which current siRNA formulations struggle to provide.
Purpose of the Study:
- To develop a novel nanostructured siRNA carrier (NSC) for sustained intracellular siRNA delivery.
- To engineer NSC's lipid matrix to control siRNA release kinetics via lysosomal enzyme degradation.
- To evaluate the efficacy of tailored NSC for prolonged survivin knockdown and prostate cancer chemosensitization.
Main Methods:
- Designed a lipid-based NSC with variable oil phase content within a solid-lipid matrix.
- Manipulated NSC degradation in lysosomes to control intracellular siRNA release rates.
- Delivered survivin-siRNA using tailored NSC to prostate cancer cells in vitro and in vivo.
Main Results:
- Tailored NSC successfully modified intracellular siRNA kinetics by controlling degradation responses.
- Survivin knockdown was extended to 9 days with the optimized NSC design.
- Achieved sustained in vitro and in vivo chemosensitization of prostate cancer to docetaxel for over a week.
Conclusions:
- The novel NSC design enables tunable intracellular siRNA kinetics for extended therapeutic effects.
- This approach addresses the limitation of short siRNA action, enabling clinically relevant dosing schedules.
- The NSC technology offers a promising strategy for enhanced prostate cancer treatment and other chronic diseases.
More Related Videos
09:09Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...